We suggest that CKD G3a-G5 patients with progressively rising or persistently elevated PTH levels should be evaluated for modifiable factors, which now includes high phosphate intake and vitamin D deficiency; treatment decisions should not be based on a single elevated value. The gene discussed is PTH; the disease is chronic kidney disease.